Page 86 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Table 5. Monitoring criteria in protocols with curative intent in chronological order of starting enrollment year (continued)
Center, Country Monitoring Gleason # biopsy cores PSA Imaging Behavioral Additional laboratory Triggers for
[Pubmed ID] schedule score /% cores indication tests interventions
Enrollment years
i
Toronto-SRCC, Every 3 mo for Histologic Subsequent PSA progression: Bone scan – PAP and Clinical,
Canada 114,125,129,130 the first 2 yr and progression: biopsies were PSA DT <2 yr, annually for serum histologic or
[11395227; every 6 mo Gleason score performed every based on at least the first 2 yr creatinine PSA progression
19917860; thereafter upgraded to 3-4 yr to identify 3 separate and biennially triggered the
20478589; ≥8 in the biologic measurements thereafter. If offer of
20846681] rebiopsy of the progression. 125 over a minimum PSA >15 treatment based
prostate at 18 of 6 mo; final ng/ml, annual on age, extent of
1995-2002 as a months post Sextant biopsies PSA >8 ng/ml; p- bone scan disease and
phase II trial; 2003- enrollment were used from value <0.05 from was comorbidities.
ongoing as an open 1995 to 2000; regression of performed.
prospective cohort since 2000, 10 ln(PSA) on time.
to 14-core TRUS was
biopsies were Protocol changes performed
performed using in PSA DT every 6 mo.
the Vienna assessment or
nomogram. 129 calculation in
1999 and after
g
2002. In 2005
the group
developed a
general linear
mixed model as
a clinical decision
making aid. h130
Memorial Sloan- Every 6 mo PSA Gleason grade >3 positive >10 – – – Treatment was
Kettering Cancer and DRE; biopsy 4 or 5 biopsy cores recommended
Center, US 115 was within 12 to (minimum 10), when the patient
[21167529] 18 mo starting biopsy core no longer met
AS and repeated containing >50% study eligibility
1997-2009 every 2 to 3 yr cancer criteria during
involvement followup.

44